Login to Your Account



Alzheimer’s disease: In the short run, no alternative to long clinical trials

By Anette Breindl
Science Editor

Monday, March 31, 2014

As Alzheimer’s drugs keep failing clinically, the consensus among researchers in the field is that for the current approach – which is focused on amyloid beta – to work, treatments will have to start earlier.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription